Platelet receptors as therapeutic targets: Past, present and future

被引：62

作者：

Jamasbi, Janina ^{[1
]}

Ayabe, Keng ^{[2
]}

Goto, Shinya ^{[2
]}

Nieswandt, Bernhard ^{[3
,4
]}

Peter, Karlheinz ^{[5
]}

Siess, Wolfgang ^{[1
,6
]}

机构：

[1] Ludwig Maximilians Univ Munchen, Inst Prevent Cardiovasc Dis, Munich, Germany

[2] Tokai Univ, Sch Med, Dept Med Cardiol, Isehara, Kanagawa, Japan

[3] Univ Wurzburg, Univ Hosp, Expt Biomed, Wurzburg, Germany

[4] Univ Wurzburg, Rudolf Virchow Ctr, Wurzburg, Germany

[5] Baker IDI Heart & Diabet Inst, Atherothrombosis & Vasc Biol, Melbourne, Vic, Australia

[6] DZHK German Ctr Cardiovasc Res, Partner Site Munich Heart Alliance, Munich, Germany

来源：

THROMBOSIS AND HAEMOSTASIS | 2017年 / 117卷 / 07期

基金：

英国医学研究理事会;

关键词：

Antiplatelet agents; GP Ib alpha; GP VI; GP IIb/IIIa; PAR-1; VON-WILLEBRAND-FACTOR; ACUTE CORONARY SYNDROMES; INDUCED THROMBUS FORMATION; INTIMA-MEDIA THICKNESS; GLYCOPROTEIN IB-ALPHA; ANTI-GPVI ANTIBODIES; CONTROLLED PHASE-II; IN-VIVO; ANTIPLATELET THERAPY; MONOCLONAL-ANTIBODY;

D O I：

10.1160/TH16-12-0911

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Anti-platelet drugs reduce arterial thrombosis after plaque rupture and erosion, prevent stent thrombosis and are used to prevent and treat myocardial infarction and ischaemic stroke. Some of them may also be helpful in treating less frequent diseases such as thrombotic thrombocytopenic purpura. The present concise review aims to cover current and future developments of anti-platelet drugs interfering with the interaction of von Willebrand factor (VWF) with glycoprotein (GP) Ib alpha, and directed against GPVI, GPIIb/IIIa (integrin alpha(IIb)beta(3)), the thrombin receptor PAR-1, and the ADP receptor P2Y(12). The high expectations of having novel antiplatelet drugs which selectively inhibit arterial thrombosis without interfering with normal haemostasis could possibly be met in the near future.

引用

页码：1249 / 1257

页数：9

共 50 条

[21] Abscisic Acid Receptors:Past,Present and Future
David J.Weston
Journal of Integrative Plant Biology, 2011, 53 (06) : 469 - 479
[22] Therapeutic antibodies: past, present and future perspectives
Reichert, Janice M.
ACTA PHARMACOLOGICA SINICA, 2006, 27 : 8 - 8
[23] Therapeutic myocardial angiogenesis: Past, present and future
Mickey Scheinowitz
Molecular and Cellular Biochemistry, 2004, 264 : 75 - 83
[24] Therapeutic Cancer Vaccines: Past, Present, and Future
Guo, Chunqing
Manjili, Masoud H.
Subjeck, John R.
Sarkar, Devanand
Fisher, Paul B.
Wang, Xiang-Yang
ADVANCES IN CANCER RESEARCH, VOL 119, 2013, 119 : 421 - 475
[25] Therapeutic myocardial angiogenesis: Past, present and future
Scheinowitz, M
MOLECULAR AND CELLULAR BIOCHEMISTRY, 2004, 264 (1-2) : 75 - 83
[26] Therapeutic communities. Past, present and future
Garelick, T
BRITISH JOURNAL OF PSYCHIATRY, 2000, 176 : 304 - 304
[27] Therapeutic antibodies: past, present and future FOREWORD
Leavy, Olive
NATURE REVIEWS IMMUNOLOGY, 2010, 10 (05) : 297 - 297
[28] Molecular modelling of drug targets: The past, the present and the future
Dahl, SG
Sylte, I
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2005, 96 (03) : 151 - 155
[29] Past, present and future targets for immunotherapy in ovarian cancer
Schwab, Carlton L.
English, Diana P.
Roque, Dana M.
Pasternak, Monica
Santin, Alessandro D.
IMMUNOTHERAPY, 2014, 6 (12) : 1279 - 1293
[30] Ion channels as targets for insecticides: Past, present and future
Narahashi, T
Aistrup, GL
Ikeda, T
Nagata, K
Song, JH
Tatebayashi, H
PROGRESS IN NEUROPHARMACOLOGY AND NEUROTOXICOLOGY OF PESTICIDES AND DRUGS, 1999, (232): : 21 - 33

← 1 2 3 4 5 →